CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

BACKGROUND: Doxorubicin-based chemotherapy is currently the most frequently used treatment for triple negative breast cancer (TNBC), yet the response rate is not high due to the lack of a biomarker allowing identification of responsive patients before the chemotherapy is initiated. We have demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Denard, Bray, Jiang, Sharon, Peng, Yan, Ye, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090630/
https://www.ncbi.nlm.nih.gov/pubmed/30103710
http://dx.doi.org/10.1186/s12885-018-4724-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090630/
https://www.ncbi.nlm.nih.gov/pubmed/30103710
http://dx.doi.org/10.1186/s12885-018-4724-8

Ejemplares similares